ARMPEarnings•prnewswire•
Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update
Sentiment:Positive (65)
Summary
Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS ANGELES, Aug. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"),...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 12, 2025 by prnewswire